Final Results From the 16‐Year Sumatriptan, Naratriptan, and Treximet Pregnancy Registry

@article{Ephross2014FinalRF,
  title={Final Results From the 16‐Year Sumatriptan, Naratriptan, and Treximet Pregnancy Registry},
  author={S. Ephross and S. Sinclair},
  journal={Headache: The Journal of Head and Face Pain},
  year={2014},
  volume={54}
}
To monitor for a signal of major teratogenicity by determining the risk of all birth major defects following in utero exposure to sumatriptan, naratriptan, and the sumatriptan/naproxen sodium combination product (tablets marketed in the United States as Treximet [GlaxoSmithKline, Research Triangle Park, NC, USA]), and to monitor for unusual patterns of defects that might suggest teratogenicity. 
Sumatriptan
  • Reactions Weekly
  • 2020
Sumatriptan
  • Reactions Weekly
  • 2020
Schwangere können Triptane nehmen
  • H. Diener
  • Medicine
  • MMW - Fortschritte der Medizin
  • 2014
Migräne: Schwangere können Triptane nehmen
  • H. Diener
  • Medicine
  • gynäkologie + geburtshilfe
  • 2014
Medical problems in pregnancy
...
1
2
3
4
...

References

SHOWING 1-10 OF 50 REFERENCES
Pregnancy Outcome Following Prescription for Sumatriptan
Pregnancy outcome following first trimester exposure to sumatriptan
Evidence‐Based Assessment of Pregnancy Outcome After Sumatriptan Exposure
Monitoring birth outcomes in the Sumatriptan Pregnancy Registry.
Nonsteroidal anti-inflammatory drugs in early pregnancy.
Pregnancy and perinatal outcomes in migraineurs using sumatriptan: a prospective study
...
1
2
3
4
5
...